Group: GcMAF Therapy

GcMAF administration is typically carried out through subcutaneous (SC) or intramuscular (IM) injections, with a recommended frequency of 2-3 times per week, as directed by the attending physician.  The preferred needle size for this procedure is either Size 26G x 1/2″ (0.45 x 13 mm) or Size 27G, along with a 2.5 ml or 1 ml syringe, which should be single-use and sterile disposable.  It’s important to highlight that the larger 2.5 ml syringe is often preferred because it reduces the distance the plunger needs to be pushed during the injection, thus improving user-friendliness.  In some cases, diabetes needles may also suffice for the administration of GcMAF, although these feature […]

One course of High Dose GcMAF is usually expected to be 48 doses for 6 months. Additional courses may be required depending on stage and type of disease, and based on disease symptoms, pathology and progress of improvement. Treatment with GcMAF should be continued as long as necessary while disease is present. Long term maintenance doses of GcMAF may be required depending on the type of disease. Maintenance doses are usually once a week or every 2 weeks administration. As a general note, macrophage activation is always necessary for the effective functioning of the immune system to stay well and disease-free. GcMAF therapy should continue while there is disease present and for […]

We recommend checking tumor markers and regular MRI, PET and CT scans. Monocyte Count: A patients monocyte count will generally rise in the early stages of GcMAF treatment and indicates a response to GcMAF. Increase in Monocyte percentage with High Dose GcMAF therapy Increase in Monocyte number with High Dose GcMAF therapy Example of monocyte count of Stage 4 Breast Cancer patient taking 0.5 ml High Dose GcMAF (1500 ng/0.5 ml) twice weekly by intramuscular injection during cancer treatment at Saisei Mirai clinics in Japan.

Second Generation GcMAF has been clinically demonstrated to be largely free of any side effects in the great majority of patients. Only low grade fever or eczema has been observed in only about 1 out of 100 patients using Second Generation GcMAF, but these were short-term effects that are significantly less than occur with most other immunotherapies. In small numbers of patients local injection site skin reactions occur which can be easily treated with a local non-steroidal anti-inflammatory patch.

Generally, yes. GcMAF can be safely used with a wide variety of other standard treatments and drugs to improve their effect. We refer to this as multimodality integrative medicine. Some therapies for cancer such as chemotherapy will reduce immune activity which will have some impact on GcMAF, however chemotherapy effectiveness can be increased in combination with GcMAF. Radiation for cancer has less negative impact on the immune system and the cancer killing effects helps macrophages to target the tumors and destroy it. In combination with anti-cancer drugs and radiation therapy (radiotherapy) is possible. For maximum effect and benefit from GcMAF, administer a few days apart from chemotherapy. Radiation therapy does […]

GcMAF is usually combination with about 5,000 IU vitamin D3 daily. Blood levels of vitamin D are often low in many kinds of diseases, such as cancer, HIV AIDS, etc. Normal vitamin D levels are necessary in order for GcMAF to work fully. Ask to have your blood 25 hydroxy-vitamin D as well as calcium levels tested. If blood calcium levels become elevated, the dose of vitamin D3 may need to be reduced to achieve optimal balance.

GcMAF can be safely used with a wide variety of drugs and other treatments.

Nagalase testing is not required for GcMAF therapy because macrophage activation is always necessary for the effective functioning of the immune system to destroy cancer cells, bacteria and viruses. GcMAF therapy should continue while there is disease present, regardless of Nagalase status.

GcMAF and/or oral MAF immunotherapy are recommended for the management of conditions characterized by immune dysfunction or compromised immune systems, including but not limited to: Cancer Autoimmune diseases Respiratory tract infections Autism Spectrum Disorders (ASD) Herpes Simplex virus (HSV) Epstein-Barr Virus (EBV) Chronic Fatigue Syndrome (CFS) Multiple sclerosis (MS) Cystitis Myalgic Encephalomyelitis (ME) Rheumatoid arthritis (RA) Urinary tract infection (UTI) Tuberculosis Lyme disease (Lyme borreliosis) Endometriosis Lupus (Systemic lupus erythematosus, SLE) Mycobacteria infections Parkinson’s disease Pneumonia infection Fibromyalgia Norovirus Malaria Warts caused by viral infection Herpes simplex virus (HSV) Q fever (Coxiella burnetii) Influenza virus (flu) Chicken pox (varicella zoster virus) Psoriasis Polycystic ovary syndrome (PCOS) Ulcerative colitis, Crohn’s disease

Cancer: For Second Generation GcMAF therapy we recommend 0.5 ml High Dose GcMAF (1500 ng/0.5 ml) 2-3 times a week in an integrative approach to treating cancer. More frequent dosing (daily or every second day) may be safely used with more advanced stage of disease, or initially in the treatment course. GcMAF may also be administered by intravenous (IV) injection, 0.5-1.0 ml 2-3 times per week in 20 ml or more saline, if deemed necessary, such as for advanced cases. We recommend IV GcMAF in addition to the usual IM/SC injections every week. These can be done on alternate days. Other diseases (such as Autism, CFS, ME, Lyme disease): We recommend 0.25 ml High Dose GcMAF (1500 ng/0.5 ml) 2-3 times […]